N Engl J Med
Oral CETP inhibitor lowers LDL in high-risk patients on maximal lipid therapy
Obicetrapib, a cholesteryl ester transfer protein inhibitor, may be a useful adjunct to lipid lowering in patients at high risk for cardiovascular events.
Study details: The randomized, double-blind, placebo-controlled BROADWAY trial (NCT05142722) evaluated the efficacy, safety, and tolerability of obicetrapib in patients at high cardiovascular risk with suboptimal LDL cholesterol (LDL-C) control. The study included 2,530 patients (mean age, 65 years; 34% women; mean baseline LDL-C, 98 mg/dL) with heterozygous familial hypercholesterolemia or ASCVD on maximally tolerated lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive either 10 mg of obicetrapib daily or matching placebo for 365 days. The primary endpoint was the percent change in LDL-C from baseline to day 84.
Results: Obicetrapib significantly reduced LDL-C levels from baseline to day 84 compared with placebo (-29.9% vs. 2.7%) for a between-group difference of -32.6 percentage points (95% confidence interval, -35.8 to -29.5; P<0.001). The treatment was well tolerated with no major safety concerns reported.
Source:
Nicholls SJ, et al; BROADWAY Investigators. (2025, May 7). N Engl J Med. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. https://pubmed.ncbi.nlm.nih.gov/40337982/